|Avita Medical Limited -- USA Stock|| |
USD 1.02 0.01 0.99%
Mr. Troy A. Barring is Chief Operating Officer of the Company. Barring has a particular brief to support the implementation of Avitas 53.9m contract with BARDA, a US federal agency that prepares for potential disasters. The contract supports various company activities in advance of a US launch, and Barring will oversee the plan to strengthen regulatory, quality, and supply chain functions. He will also manage other key operational aspects of the Company, to support its global commercialisation activities in territories where it is already inmarket.
COO Since 2016
The company has return on total asset (ROA)
of (97.34) %
which means that it has lost $97.34 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (192.26) %
meaning that it generated substantial loss on money invested by shareholders.
Avita Medical Limited, a medical device company, develops and distributes regenerative products for the treatment of a range of wounds, scars, and skin defects in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It also offers ReGenerCell for chronic wounds and ReNovaCell for pigmentation. Avita Medical is traded on OTC Market in USA.Avita Medical Limited (AVMXY) is traded on OTC Market in USA. It is located in 28159 Avenue Stanford and employs 37 people.